Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore's first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore.
SingHealth Duke-NUS Academic Medical Centre and Cordlife partner to advance stem cell technology to first-in-man clinical trial in Singapore asiaresearchnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaresearchnews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Upon collection after the delivery of a baby, cord blood is processed to extract stem cells and to prepare it for long-term cryopreservation view more
Credit: Cordlife Group Limited
SINGAPORE, 11 May 2021 - Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore s first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore. This is the first time a home-grown UCB cell therapy is being tested on humans. The technology has the potential to increase treatment options for patients suffering from blood cancers or blood-related conditions.